NCI Cancer Bulletin Home Page - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI

	Subscribe Now


	To begin your free subscription to the NCI Cancer Bulletin, enter your e-mail address below: Your email address

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	Send to a Colleague


	Do you know someone who would enjoy receiving the NCI Cancer Bulletin? Send to (e-mail address): Your e-mail address: Your name:

	Other NCI Newsletters


	Connections (CCR) Linkage (DCEG) BenchMarks (OMR)

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Inside the Current Issue

Director's Update
The Dawn of Personalized Oncology

Mobilizing National Drug Discovery

Personalized Drug Development

A New Paradigm for Drug Discovery

Treatment Arsenal Expands with Small Chemicals

CMap Extends Drug Use

Clinical Trials and Personalized Drugs

Collaborating with Industry to Drive Drug Development

Helping Technology Collaborations Flourish

Other Resources

Cancer Research Highlights
Breast Cancer Relapse Risk Low after Chemotherapy or Tamoxifen

Novel Monoclonal Antibody Effective in Some Relapsed NHL Patients

Cord-Blood Transplant into Bone Restores Blood Counts

Esophageal Adenocarcinoma Rates Rise in Men and Women

Suicide Risk Higher in Cancer Patients than the General Population

Vitamin C Injections Slow Tumor Growth in Mice

NCI Cancer Bulletin

     View Online Version (HTML)

     View PDF Version

     View Bulletin Archive/Search

| | | | | | | |

A Service of the National Cancer Institute